Protection by Immunoglobulin Dual-Affinity Retargeting Antibodies against Dengue Virus
Protection by Immunoglobulin Dual-Affinity Retargeting Antibodies against Dengue Virus
复制标题
DOI：
10.1128/jvi.00327-13
复制
发表时间：
2013-07-01
影响因子：
5.4
通讯作者：
Diamond, Michael S.
中科院分区：
文献类型：
--
作者：
Brien, James D.;Sukupolvi-Petty, Soila;Diamond, Michael S.
登革热病毒是最常见的节肢动物传播的病毒感染，估计每年有3.9亿人感染，类似于36亿人面临风险。目前，还没有获得批准的疫苗或治疗药物来控制全球登革热病毒疾病的负担。在这项研究中，我们展示了一种新型的双特异性双亲和重定向分子(DART)的结合、中和活性和治疗能力，该分子可以限制所有四种血清型登革病毒的感染。
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and similar to 3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.